ANVS Stock Price
Annovis Bio, Inc.
ANVS stock price is $1.02 (-3.77% on the day), giving Annovis Bio, Inc. a market cap of $43.53M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ANVS Stock Overview
- Price
- $1.02
- Previous close
- $1.06
- Open
- $1.05
- Market cap
- $43.53M
- P/E ratio
- -1.5
- 52-week range
- $1.04 - $5.50
- 1-year price target
- $10.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NYE
- MarketXLS Rank
- 21
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANVS | $1.02 | -3.8% | 843.70K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |